10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

# PRTN3 Blocking Peptide (C-term)

**Synthetic peptide**
**Catalog # BP22068b**

## Specification

### PRTN3 Blocking Peptide (C-term) - Product Information

Primary Accession P24158

### PRTN3 Blocking Peptide (C-term) - Additional Information

**Gene ID** 5657

**Other Names**
Myeloblastin, 3.4.21.76, AGP7, C-ANCA antigen, Leukocyte proteinase 3, PR-3, PR3, Neutrophil proteinase 4, NP-4, P29, Wegener autoantigen, PRTN3, MBN

**Target/Specificity**
The synthetic peptide sequence is selected from aa 108-118 of HUMAN PRTN3

**Format**
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

### PRTN3 Blocking Peptide (C-term) - Protein Information

**Name** PRTN3

**Synonyms** MBN

**Function**
Serine protease that degrades elastin, fibronectin, laminin, vitronectin, and collagen types I, III, and IV (in vitro) (PubMed:<a href="http://www.uniprot.org/citations/3198760" target="_blank">3198760</a>, PubMed:<a href="http://www.uniprot.org/citations/2033050" target="_blank">2033050</a>, PubMed:<a href="http://www.uniprot.org/citations/28240246" target="_blank">28240246</a>). By cleaving and activating receptor F2RL1/PAR-2, enhances endothelial cell barrier function and thus vascular integrity during neutrophil transendothelial migration (PubMed:<a href="http://www.uniprot.org/citations/23202369" target="_blank">23202369</a>). May play a role in neutrophil transendothelial migration, probably when associated with CD177 (PubMed:<a href="http://www.uniprot.org/citations/22266279" target="_blank">22266279</a>).

**Cellular Location**

Cytoplasmic granule. Secreted. Cell membrane; Peripheral membrane protein; Extracellular side. Membrane raft; Peripheral membrane protein; Extracellular side. Note=Localizes predominantly to azurophil granules (primary secretory granules) in neutrophils (PubMed:2033050, PubMed:3198760, PubMed:7897245, PubMed:18462208) Secreted upon neutrophil stimulation by TNF-alpha, lipopolysaccharide (LPS), fMLP and CXCL8/IL8 or during neutrophil transmigration (PubMed:22266279, PubMed:28240246). Following secretion tethered to the cell membrane by CD177 (PubMed:18462208, PubMed:22266279)

**Tissue Location**
Expressed in polymorphonuclear leukocytes (at protein level) (PubMed:2033050, PubMed:7897245, PubMed:3198760) Expressed in neutrophils (at protein level) (PubMed:28240246, PubMed:18462208, PubMed:21193407, PubMed:22266279, PubMed:17244676) Expressed in differentiating neutrophils (PubMed:18462208)

## PRTN3 Blocking Peptide (C-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

## PRTN3 Blocking Peptide (C-term) - Images

## PRTN3 Blocking Peptide (C-term) - Background

Polymorphonuclear leukocyte serine protease that degrades elastin, fibronectin, laminin, vitronectin, and collagen types I, III, and IV (in vitro) and causes emphysema when administered by tracheal insufflation to hamsters.

## PRTN3 Blocking Peptide (C-term) - References

Labbaye C.,et al.Proc. Natl. Acad. Sci. U.S.A. 88:9253-9256(1991).
Grimwood J.,et al.Nature 428:529-535(2004).
Mural R.J.,et al.Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
Zimmer M.,et al.Proc. Natl. Acad. Sci. U.S.A. 89:8215-8219(1992).
Sturrock A.B.,et al.J. Biol. Chem. 267:21193-21199(1992).